IRD · XBRL financial data

Opus Genetics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IRD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	0	589	39,850	19,049	10,992	14,196
General and administrative	2,818	8,121	7,269	11,959	18,215	21,983
Total operating expenses	19,968	23,294	21,624	29,612	73,066	52,795
Operating income (loss)	(19,968)	(22,705)	18,226	(10,563)	(62,074)	(38,599)
Interest expense	6,847	2	9	0	0	129
Other income (expense)	9	(157)	(14)	1,837	4,470	1,989
Income tax expense (benefit)	0	0	315	12	0	0
Net income (loss)	(24,620)	(56,693)	17,888	(9,986)	(57,532)	(49,591)
Earnings per share, basic USD per share	(5.28)	(3.82)	0.90	(0.46)	(2.15)	(0.80)
Earnings per share, diluted USD per share	(5.28)	(3.82)	0.87	(0.46)	(2.15)	(0.80)
Weighted average shares, basic thousands of shares	4,661	14,853	19,931	21,590	26,716	62,222
Weighted average shares, diluted thousands of shares	4,661	14,853	20,597	21,590	26,716	62,222

Fiscal years (IRD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	16,399	24,534	42,634	50,501	30,321	45,091
Short-term investments	0	219	49	15	2	0
Accounts receivable	0	0	1,298	926	3,563	1,995
Prepaid and other current assets	1,269	1,314	1,453	1,099	515	1,788
Total current assets	17,668	26,067	48,986	53,948	36,610	50,044
Property and equipment, net	14	10	6	0	252	199
Total assets	17,682	26,077	48,992	53,948	36,862	50,243
Accounts payable	1,214	1,584	1,069	2,153	3,148	3,293
Accrued liabilities	1,971	1,733	1,684	1,815	8,145	4,488
Total current liabilities	3,185	3,855	2,753	4,042	11,295	7,781
Long-term debt	—	—	—	—	0	1,129
Total liabilities	31,149	3,855	2,753	4,042	11,295	34,895
Accumulated deficit	(32,675)	(89,368)	(71,480)	(81,466)	(138,998)	(188,589)
Total stockholders' equity	(13,467)	22,222	46,239	49,906	6,724	15,348
Total liabilities and equity	17,682	26,077	48,992	53,948	36,862	50,243
Common shares outstanding (cover page) thousands of shares	10,930	18,990	20,948	24,813	45,484	71,149

Fiscal years (IRD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(24,620)	(56,693)	17,888	(9,986)	(57,532)	(49,591)
Stock-based compensation	1,506	1,914	1,807	3,510	3,362	3,399
Net cash from operating activities	(6,797)	(19,370)	14,314	(1,112)	(25,576)	(35,253)
Purchases of property and equipment	0	—	—	—	—	—
Net cash from investing activities	539	(100)	0	0	1,210	0
Proceeds from issuing common stock	0	28,491	4,428	9,227	4,497	5,805
Net cash from financing activities	21,120	27,605	3,786	8,979	4,186	50,023

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
Fortress Biotech	196,576	18,718	(59,277)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Actinium Pharmaceuticals	36,473	35,000	(5,179)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Lite Strategy	5,706	not reported	(1,164)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
Astria Therapeutics	96,280	706	(32,295)*	57.1M	7.1 quarters	Q3 FY25 10-QSep 30, 2025
Actuate Therapeutics	4,426	not reported	(4,405)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.